| A randomized trial of bevacizumab for newly diagnosed glioblastoma MR Gilbert, JJ Dignam, TS Armstrong, JS Wefel, DT Blumenthal, ... New England Journal of Medicine 370 (8), 699-708, 2014 | 3143 | 2014 |
| Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma H Noushmehr, DJ Weisenberger, K Diefes, HS Phillips, K Pujara, ... Cancer cell 17 (5), 510-522, 2010 | 2822 | 2010 |
| Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment Q Wang, B Hu, X Hu, H Kim, M Squatrito, L Scarpace, AC DeCarvalho, ... Cancer cell 32 (1), 42-56. e6, 2017 | 1714 | 2017 |
| The transcriptional network for mesenchymal transformation of brain tumours MS Carro, WK Lim, MJ Alvarez, RJ Bollo, X Zhao, EY Snyder, EP Sulman, ... Nature 463 (7279), 318-325, 2010 | 1435 | 2010 |
| m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program S Zhang, BS Zhao, A Zhou, K Lin, S Zheng, Z Lu, Y Chen, EP Sulman, ... Cancer cell 31 (4), 591-606. e6, 2017 | 1348 | 2017 |
| Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma KPL Bhat, V Balasubramaniyan, B Vaillant, R Ezhilarasan, K Hummelink, ... Cancer cell 24 (3), 331-346, 2013 | 1170 | 2013 |
| Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial A Mahajan, S Ahmed, MF McAleer, JS Weinberg, J Li, P Brown, S Settle, ... The lancet oncology 18 (8), 1040-1048, 2017 | 729 | 2017 |
| Treatment for brain metastases: ASCO-SNO-ASTRO guideline MA Vogelbaum, PD Brown, H Messersmith, PK Brastianos, S Burri, ... Neuro-Oncology 24 (3), 331-357, 2022 | 519 | 2022 |
| MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma AL Rivera, CE Pelloski, MR Gilbert, H Colman, C De La Cruz, EP Sulman, ... Neuro-oncology 12 (2), 116-121, 2010 | 518 | 2010 |
| IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection J Beiko, D Suki, KR Hess, BD Fox, V Cheung, M Cabral, N Shonka, ... Neuro-oncology 16 (1), 81-91, 2014 | 504 | 2014 |
| Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non–small-cell lung cancer JW Welsh, R Komaki, A Amini, MF Munsell, W Unger, PK Allen, JY Chang, ... Journal of Clinical Oncology 31 (7), 895-902, 2013 | 500 | 2013 |
| Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype K Gabrusiewicz, B Rodriguez, J Wei, Y Hashimoto, LM Healy, SN Maiti, ... JCI insight 1 (2), e85841, 2016 | 455 | 2016 |
| A multigene predictor of outcome in glioblastoma H Colman, L Zhang, EP Sulman, JM McDonald, NL Shooshtari, A Rivera, ... Neuro-oncology 12 (1), 49-57, 2010 | 441 | 2010 |
| The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma KPL Bhat, KL Salazar, V Balasubramaniyan, K Wani, L Heathcock, ... Genes & development 25 (24), 2594-2609, 2011 | 417 | 2011 |
| TERT promoter mutations and risk of recurrence in meningioma F Sahm, D Schrimpf, A Olar, C Koelsche, D Reuss, J Bissel, A Kratz, ... Journal of the National Cancer Institute 108 (5), djv377, 2016 | 399 | 2016 |
| Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer MC Pietanza, SN Waqar, LM Krug, A Dowlati, CL Hann, A Chiappori, ... Journal of Clinical Oncology 36 (23), 2386-2394, 2018 | 391 | 2018 |
| Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma CE Pelloski, KV Ballman, AF Furth, L Zhang, E Lin, EP Sulman, K Bhat, ... Journal of Clinical Oncology 25 (16), 2288-2294, 2007 | 387 | 2007 |
| IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas A Olar, KM Wani, KD Alfaro-Munoz, LE Heathcock, HF van Thuijl, ... Acta neuropathologica 129, 585-596, 2015 | 384 | 2015 |
| A region of consistent deletion in neuroblastoma maps within human chromosome 1p36. 2-36.3. PS White, JM Maris, C Beltinger, E Sulman, HN Marshall, M Fujimori, ... Proceedings of the National Academy of Sciences 92 (12), 5520-5524, 1995 | 321 | 1995 |
| Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes K Gabrusiewicz, X Li, J Wei, Y Hashimoto, AL Marisetty, M Ott, F Wang, ... Oncoimmunology 7 (4), e1412909, 2018 | 303 | 2018 |
Kenneth AldapeNational Cancer Institutenih.gov의 이메일 확인됨
